VSTM241220C20000
- 0.05
- 0.000.00%
Verastem Newsroom
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem (VSTM) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential
Verastem Analyst Ratings
Guggenheim Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $13
Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity
HC Wainwright & Co. Maintains Buy on Verastem, Lowers Price Target to $7
Verastem Analyst Ratings
Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism
Verastem Analyst Ratings
RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating
Buy Rating Justified by Verastem's Promising LGSOC Drug Prospects and Strong Market Position
Mizuho Adjusts Price Target on Verastem to $7 From $36 Following Model Update, Maintains Outperform Rating